# FBXW7

Source: https://onco.cc/targets/fbxw7/  
OnCo record `fbxw7` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

FBXW7 (F-box/WD repeat-containing protein 7) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Non-Hodgkin lymphoma, Endometrial cancer and 5 more.

## Summary

Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Recognises and binds phosphorylated sites/phosphodegrons within target proteins and thereafter brings them to the SCF complex for ubiquitination. Identified substrates include cyclin-E (CCNE1 or CCNE2), DISC1, JUN, MYC, NOTCH1 released notch intracellular domain (NICD), NFE2L1, NOTCH2, MCL1, MLST8, RICTOR, and probably PSEN1.

CIViC holds 14 clinical evidence items and 0 assertions across 12 variants, naming Regorafenib Anhydrous, Cetuximab, Panitumumab and Everolimus and others. Open Targets scores its association with cancer at 0.83 (direct and indirect evidence; datatypes genetic literature 0.41, affected pathway 0.75, literature 0.99, genetic association 0.55, somatic mutation 0.98, animal model 0.45). IntOGen calls it a driver in 42 cohorts (11 activating, 30 loss-of-function), covering Anal Squamous Cell Carcinoma, Bladder Urothelial Carcinoma, Invasive Breast Carcinoma, Cervical Adenocarcinoma, Cervical Squamous Cell Carcinoma, Cholangiocarcinoma and others.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: F-box and WD repeat domain containing 7; F-box/WD repeat-containing protein 7; FLJ11071; SEL-10; SEL10; FBW7; FBX30; CDC4; FBXW6
- Tags: cancer-genes-wave
- Symbol: FBXW7
- Class: tumor-suppressor
- Biology: Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Recognises and binds phosphorylated sites/phosphodegrons within target proteins and thereafter brings them to the SCF complex for ubiquitination. Identified substrates include cyclin-E (CCNE1 or CCNE2), DISC1, JUN, MYC, NOTCH1 released notch intracellular domain (NICD), NFE2L1, NOTCH2, MCL1, MLST8, RICTOR, and probably PSEN1. Acts as a negative regulator of JNK signalling by binding to phosphorylated JUN and promoting its ubiquitination and subsequent degradation. Involved in bone homeostasis and negative regulation of osteoclast differentiation. Regulates the amplitude of the cyclic expression of hepatic core clock genes and genes involved in lipid and glucose metabolism via ubiquitination and proteasomal degradation of their transcriptional repressor NR1D1; CDK1-dependent phosphorylation of NR1D1 is necessary for SCF(FBXW7)-mediated ubiquitination. Location: Nucleus, nucleoplasm; Chromosome; Cytoplasm; Nucleus, nucleolus (UniProt). Locus 4q31.3 (HGNC).
- Where found: Colorectal cancer: Open Targets association 0.76 with colorectal cancer (MONDO_0005575); CIViC evidence names this disease; Non-Hodgkin lymphoma: Open Targets association 0.68 with non-Hodgkin lymphoma (MONDO_0018908); Endometrial cancer: Open Targets association 0.67 with endometrial cancer (MONDO_0011962); IntOGen driver in 4 cohorts (UCEC); Breast cancer: Open Targets association 0.51 with breast cancer (MONDO_0007254); IntOGen driver in 4 cohorts (BRCA); Leukaemia: Open Targets association 0.63 with leukaemia (MONDO_0005059); Cervical cancer: Open Targets association 0.62 with cervical cancer (MONDO_0002974); IntOGen driver in 3 cohorts (CEAD, CESC)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 6 therapies; IntOGen calls it an activating (Act) driver in 11 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 30 cohorts; CIViC holds 14 clinical evidence items on its variants; UniProt keyword "DNA repair". Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: T-cell Acute Lymphoblastic Leukaemia.

## Sources

- HGNC HGNC:16712: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16712
- UniProt Q969H0: https://www.uniprot.org/uniprotkb/Q969H0/entry
- NCBI Gene 55294: https://www.ncbi.nlm.nih.gov/gene/55294
- Ensembl ENSG00000109670: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000109670

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Cervical cancer](https://onco.cc/cancers/cervical/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)

---
JSON: https://onco.cc/api/v1/entities/fbxw7.json